Evidence map›Paper›PMID 41107520›Full record

ArticleNature biomedical engineering2026

Deep-learning-based HER2 status assessment from multimodal breast cancer data predicts neoadjuvant therapy response.

Jiadong Zhang, Yonghao Li, Zheren Li, Zhiming Cui, Pinxiong Li, Jun Li, Zhen Li, Yu Xie, Kannie W Y Chan, Qinrong Zhang and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jiadong Zhang *School of Biomedical Engineering and State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai, China.ORCID http://orcid.org/0000-0001-6305-4928
Yonghao Li *School of Biomedical Engineering and State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai, China.
Zheren Li *School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.ORCID http://orcid.org/0000-0003-3787-3940
Zhiming CuiSchool of Biomedical Engineering and State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai, China.
Pinxiong LiDepartment of Radiology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Jun LiDepartment of Radiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Zhen LiThird Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China.
Yu XieDepartment of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China.
Kannie W Y ChanDepartment of Biomedical Engineering, City University of Hong Kong, Hong Kong, China. KannieW.Y.C@cityu.edu.hk.ORCID http://orcid.org/0000-0002-7315-1550
Qinrong ZhangDepartment of Biomedical Engineering, City University of Hong Kong, Hong Kong, China. qzhan32@cityu.edu.hk.ORCID http://orcid.org/0000-0001-8893-514X
Zhenhui LiDepartment of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China. lizhenhui@kmmu.edu.cn.ORCID http://orcid.org/0009-0009-3613-9403
Dinggang ShenSchool of Biomedical Engineering and State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai, China. dgshen@shanghaitech.edu.cn.ORCID http://orcid.org/0000-0002-7934-5698

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate assessment of human epidermal growth factor receptor 2 (HER2) status is crucial for effective breast cancer treatment planning and improved patient outcomes. Traditional needle biopsies, limited in tissue sampling, often lead to inaccurate assessments due to intratumoural heterogeneity. Here, to address this, we introduce the deep-learning-based HER2 multimodal alignment and prediction (MAP) model, which leverages pretreatment multimodal breast cancer images for a more comprehensive reflection of tumour characteristics and provides more accurate HER2 status prediction. We develop patient response MAP models to demonstrate the HER2 prediction performance of our model compared with needle biopsies from patients receiving neoadjuvant therapy. A large-scale multimodal breast cancer dataset from 4 centres, consisting of 14,472 images from 6,991 cases, is adopted in this study, and the results consistently demonstrate the superiority of our HER2 MAP model in predicting patient response. These findings highlight the substantial advantages of our HER2 predictions. Our study provides physicians with a crucial tool for informed clinical decisions and treatment plans, aiming to improve outcomes in patients with breast cancer.

Indexed as

Breast NeoplasmsDeep LearningErb-b2 Receptor Tyrosine KinasesNeoadjuvant TherapyFemaleHumansPrediction AlgorithmsPredictive Learning ModelsTreatment OutcomeERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.